Women who have been infected by two different strains of HIV from two different sexual partners – a condition known as HIV superinfection – have more potent antibody responses that block the replication of the virus compared to women who have been infected only once, a new study shows.
The study suggests that harboring a mixture of different viral strains may be one way to promote a robust antibody response -- and eventually a vaccine.
The full findings, by researchers at Fred Hutchinson Cancer Research Center in Seattle, will be published online Thursday in PLoS Pathogens, the research center said Tuesday.
“We found that women who had been infected twice not only had more potent antibody responses, but some of these women had ‘elite’ antibody activity, meaning that they had a broad and potent ability to neutralize a wide variety of strains of HIV over a sustained period time,” said senior author Julie Overbaugh, a member of the Hutchinson Center’s Human Biology Division.
It is estimated that only about 1 percent of people with HIV are so-called “elite neutralizers,” who are able to potently neutralize multiple subtypes of the virus.
“Individuals who become superinfected with a second virus from a different partner represent a unique opportunity for studying the antibody response and may provide insights into the process of developing broad neutralizing antibodies that could inform HIV-vaccine design,” she said.
The researchers tracked the immune activity of 12 superinfected women from Mombasa, Kenya, over a five-year period and compared each to a control group of three singly infected women.
Overbaugh and fellow author Valerie Cortez, a doctoral student in her lab, assessed the ability of antibodies present in superinfected and singly infected women to neutralize a spectrum of circulating HIV-1 variants. In doing so they were able to determine whether the presence of two viruses compared to one made a difference in immune response.
The study found that superinfected women had, on average, 1.68 times more neutralizing antibodies than non-superinfected women, and they scored much higher in their ability to neutralize the virus – superinfected women had 1.46 times greater potency than the singly infected women.
More than 1.1 million Americans are estimated to be living with HIV today, and every 9.5 minutes someone in the United States becomes infected, according to the U.S. Department of Health and Human Services.
An HIV vaccine is considered the best approach to long-term protection from HIV infection, but attempts to develop such a vaccine so far have meet with limited success.
“The holy grail of an HIV vaccine is to elicit antibodies to the virus because antibodies have been shown to block virus infection. But there has been little progress in determining how to elicit such antibodies with a vaccine. The study of individuals HIV infected who have developed strong antibody responses to the virus may shed light on the best approach to design a vaccine that will induce an effective immune response,” Overbaugh said.The National Institutes of Health and the Howard Hughes Medical Institute supported the research, which involved collaborators at the University of Washington and the University of Nairobi in Kenya.